Favipiravir pharmacokinetics in Thai adults with mild COVID ‐19: A sub‐study of interpatient variability and ethnic differences in exposure
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.1233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Ing-Orn Prasanchaimontri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Bureau of Drug and Narcotic, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand. Hauptthemen laut MEDLINE: Amides, Antiviral Agents, COVID-19 Drug Treatment, Pyrazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Siriraj Research and Development Fund.
Abstract (Originalsprache)
This sub‐study sought to characterize the pharmacokinetics (PK) of favipiravir (FPV) within Thai adults and quantitatively assess differences in exposure to those previously reported in other populations as a basis to understand putative differences in efficacy between studies conducted in different regions. It was nested within a prospective trial of adults with symptomatic COVID‐19 infection without pneumonia receiving 1800 mg FPV twice‐daily on day 1 and 800 mg twice‐daily thereafter. Individual PK profiles were fitted with a one‐compartment disposition model (first‐order absorption). Eight adults (seven female) with a median age of 39 years and BMI of 27.9 kg/m 2 were included. Seven adults achieved plasma concentrations above the EC 90 in vitro target (25 mg/L), with minimum–maximum concentrations decreasing with repeat dosing. The mean FPV apparent clearance observed in this study was 1.1 L/h (coefficient of variation [CV]: 60%), apparent volume of distribution 20.6 L (CV: 40%), absorption rate constant 6.1 h (CV: 100%), and 2.4 daily % change in apparent clearance (CV: 315%). Higher exposures were observed in these Thai adults compared with data from previous studies in Chinese, Japanese, and Turkish populations, respectively. Current FPV doses recommended in Thailand achieved target plasma concentrations with higher exposures than those described previously in other populations. The limited sample size prohibits firm conclusions from being drawn but the presented data warrants confirmation with a view to interrogate the appropriateness of doses used in randomized clinical trials that failed to demonstrate efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bureau of Drug and Narcotic, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
- Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
- Department of Pharmacology and Therapeutics, Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK.
- Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Nakhon Pathom, Thailand.
- Siriraj Institute of Clinical Research (SICRES), Mahidol University, Nakhon Pathom, Thailand.
- Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Nakhon Pathom, Thailand.
ORCID-Profile: Ing-Orn Prasanchaimontri, Weerawat Manosuthi, Andrew Owen, Suvimol Niyomnaitham, Rujipas Sirijatuphat, Lantharita Charoenpong, Tim R Cressey, Katherine Copeland, Phongpan Mokmued, Kulkanya Chokephaibulkit
Förderung
- NIAID NIH HHS
- NIH HHS
- Siriraj Research and Development Fund
- National Research Council of Thailand
- Wellcome Trust
Zitieren
APA
Prasanchaimontri, I. O., Manosuthi, W., Pertinez, H., Owen, A., Niyomnaitham, S., Sirijatuphat, R., Charoenpong, L., Cressey, T. R., Copeland, K., Mokmued, P., & Chokephaibulkit, K. (2024). Favipiravir pharmacokinetics in Thai adults with mild COVID ‐19: A sub‐study of interpatient variability and ethnic differences in exposure. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1233
Vancouver
Prasanchaimontri IO, Manosuthi W, Pertinez H, Owen A, Niyomnaitham S, Sirijatuphat R, et al. Favipiravir pharmacokinetics in Thai adults with mild COVID ‐19: A sub‐study of interpatient variability and ethnic differences in exposure. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1233
BibTeX
@article{Prasanchaimontri2024,
author = {Prasanchaimontri, Ing-Orn and Manosuthi, Weerawat and Pertinez, Henry and Owen, Andrew and Niyomnaitham, Suvimol and Sirijatuphat, Rujipas and Charoenpong, Lantharita and Cressey, Tim R and Copeland, Katherine and Mokmued, Phongpan and Chokephaibulkit, Kulkanya},
title = {Favipiravir pharmacokinetics in Thai adults with mild COVID ‐19: A sub‐study of interpatient variability and ethnic differences in exposure},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.1233}
}
EUVIMED